Evidence map›Paper›PMID 29616452›Full record

ArticleInflammopharmacology2018

Flavonoid quercetin-methotrexate combination inhibits inflammatory mediators and matrix metalloproteinase expression, providing protection to joints in collagen-induced arthritis.

Nagaraja Haleagrahara, Kelly Hodgson, Socorro Miranda-Hernandez, Samuel Hughes, Anupama Bangra Kulur, Natkunam Ketheesan

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Research advances ofFrontiers in immunology · 2024
    Review
  12. Integrative multi-target analysis ofIn silico pharmacology · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Molecules (Basel, Switzerland) · 2023
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Nagaraja HaleagraharaDiscipline of Biomedicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, James Cook Drive, Townsville, QLD, 4811, Australia. haleagrahara.nagaraja@jcu.edu.au.ORCID http://orcid.org/0000-0001-8702-0490
Kelly HodgsonDiscipline of Biomedicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, James Cook Drive, Townsville, QLD, 4811, Australia.
Socorro Miranda-HernandezDiscipline of Biomedicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, James Cook Drive, Townsville, QLD, 4811, Australia.
Samuel HughesDiscipline of Biomedicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, James Cook Drive, Townsville, QLD, 4811, Australia.
Anupama Bangra KulurDiscipline of Biomedicine, College of Public Health, Medical and Veterinary Sciences, James Cook University, James Cook Drive, Townsville, QLD, 4811, Australia.
Natkunam KetheesanSchool of Science and Technology, University of New England, Armidale, NSW, 2351, Australia.
James Cook University · AUAustralian Institute of Tropical Health and Medicine · AUUniversity of New England · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of synovial tissues in joints, leading to progressive destruction of cartilage and joints. The disease-modifying anti-rheumatic drugs currently in use have side-effects. Thus, there is an urgent need for safe anti-inflammatory therapies for RA. This study aimed to evaluate the therapeutic effect of the flavonoid quercetin on arthritis in mice immunized with type II collagen (CII). An arthritis model was established in C57/BL6 mice by intradermal administration of chicken CII mixed with Freund's complete adjuvant. Quercetin (30 mg/kg orally) and methotrexate (0.75 mg intraperitoneally twice a week) were administered to investigate their protective effects against collagen-induced arthritis (CIA). Levels of tumour necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), IL-6, and the matrix metalloproteinases (MMP), 3, and 9 were detected to assess the anti-inflammatory effect of quercetin. The mRNA expression of MMP3, MMP9, CCL2, and TNF-α was also measured by quantitative real-time PCR. Quercetin significantly alleviated joint inflammation by reducing the levels of circulating cytokines and MMPs. There was a significant decrease in the expression of TNFα and MMP genes in the ankle joints of arthritic mice. A significant reduction in the levels of knee-joint inflammatory mediators were observed with combined quercetin and methotrexate treatment. Thus, quercetin has the potential to prevent joint inflammation and could be used as an adjunct therapy for RA patients who have an inadequate response to anti-rheumatic monotherapy.

Indexed as

AnimalsAnkle JointArthritis, ExperimentalArthritis, RheumatoidC-Reactive ProteinDrug Therapy, CombinationFemaleInflammation MediatorsKnee JointMaleMatrix Metalloproteinase InhibitorsMethotrexateMiceQuercetinC-Reactive ProteinInflammation MediatorsMatrix Metalloproteinase InhibitorsMethotrexateQuercetinFlavonoidsInflammationMethotrexateQuercetinRheumatoid arthritis

Identifiers

PMID29616452
OpenAlexW2796115239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.